Evidence map›Paper›PMID 27210811›Full record

ArticleAntiviral research2016

Inhibition of human norovirus by a viral polymerase inhibitor in the B cell culture system and in the mouse model.

Abimbola O Kolawole, Joana Rocha-Pereira, Michael D Elftman, Johan Neyts, Christiane E Wobus

Abstract read
In one paragraph

Article in Antiviral research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Review
  2. Applied and environmental microbiology · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. A Bibliometric Analysis of the Literature on Norovirus Disease from 1991-2021.International journal of environmental research and public health · 2022
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Birth Cohort Studies: Toward Understanding Protective Immunity to Human Noroviruses.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abimbola O KolawoleDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA.
Joana Rocha-PereiraKU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium.
Michael D ElftmanDepartment of Biomedical and Diagnostic Sciences, University of Detroit Mercy School of Dentistry, Detroit, MI, USA.
Johan NeytsKU Leuven - University of Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000, Leuven, Belgium.
Christiane E WobusDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA. Electronic address: cwobus@umich.edu.

Funding

Mechanisms of Norovirus EntryR01AI080611 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WOBUS, CHRISTIANE · 2009 to 2012
$1.5M
Development of a human norovirus cell culture modelR21AI110907 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WOBUS, CHRISTIANE · 2015 to 2016
$415k
NIAID NIH HHS R01 AI080611NIAID NIH HHS R21 AI110907
6 · The paper itself

Abstract

The recently developed human norovirus (HuNoV) B cell culture and mouse models hold promise for drug discovery and development but their suitability for antiviral studies has not been assessed. We demonstrate the inhibitory effect of the nucleoside analogue 2'-C-methylcytidine (2CMC) on HuNoV replication in the human B cell BJAB cell line and in Balb/c Rag/gamma chain-deficient (Rag-γc(-/-)) mice. These data suggest the applicability of both models for future study and development of antiviral drugs for the treatment of HuNoV infections.

Indexed as

AnimalsAntiviral AgentsB-LymphocytesCaliciviridae InfectionsCell LineDisease Models, AnimalHumansMiceMice, KnockoutNorovirusVirus ReplicationAntiviral AgentsAntiviralEnteric virusHuman norovirusPolymerase inhibitorPositive-sense RNA virus

Identifiers

PMID27210811
PMCPMC4980194

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.